Biomedical engineers at Duke University have developed an AI-based platform that designs short proteins, termed peptides, capable of binding and destroying previously undruggable disease-causing ...

This article explores methods to enhance efficiency in the drug discovery and development pipeline, focusing on optimizing ...

Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...

A new study led by researchers from Moffitt Cancer Center, in collaboration with investigators from the University of ...

Andrew Pierce, senior executive at French biotech Owkin, on how artificial intelligence can make the drug development process ...

Acellera Therapeutics and Psivant Therapeutics have announced a strategic research partnership aimed at developing computational drug discovery approaches with the help of AI and quantum simulations.

Ainnocence has achieved significant milestones in applying artificial intelligence to accelerate antibody discovery for ...

Rakovina Therapeutics Inc. , a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced its participation in the ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

The AlphaMeld platform empowers key functional stakeholders, including those involved in early drug discovery, target identification, competitive intelligence, and clinical trial optimization. By ...